Table 1.
Clinical characteristics of the study population according to survival
| Total | Survival 2 years | |
|---|---|---|
| Yes (alive) | No (dead) | |
| 23 (41) | 33 (59) | |
| Gender | ||
| Men | 11 (20) | 22 (39) |
| Women | 12 (21) | 11 (20) |
| Age, years, Median (range) | 60 (27–83) | 67 (38–84) |
| M stage M1a/b | 9 (38) | 4 (14) |
| M1c | 14 (62) | 29 (86)* |
| Organs involved ≤ 2 | 16 (29) | 13 (23) |
| >2 | 7 (12) | 20 (36) |
| BRAF v600 Mutation, No | 8 (14) | 17 (30) |
| Yes | 12 (21) | 13 (23) |
| Unknown | 3 (5) | 3 (5) |
| LDH, normal | 19 (34) | 14 (25) |
| >ULN† | 4 (7) | 19 (34)** |
| Number of treatments before inclusion, 0 | 11 (20) | 18 (32) |
| 1 | 9 (16) | 13 (23) |
| 2 | 2 (4) | 1 (1·7) |
| 3 | 1 (1·7) | 1 (1·7) |
| ANC# | 4·7 (1·7) | 4·8 (1·4) |
| AEC# | 0·1 (0·1) | 0·1 (0·1) |
| ALC# | 1·6 (0·5) | 1·4 (0·6) |
| Increase AEC | 13 (57) | 18 (55) |
| Increase ALC | 17 (74) | 16 (49) |
| irAE | 8 (35) | 15 (46) |
Data are shown as number of patients (%) unless otherwise indicated.
†
ULN = upper limit of normal,
#
mean (standard deviation).
*
P < 0·05;
**
P < 0·01 versus survivors.
ANC = absolute neutrophil count (109/l); AEC = absolute eosinophil count (109/l); ALC = absolute lymphocyte count (109/l); irAE = immune‐related adverse event; LDH = lactate dehydrogenase (U/l); M stage = metastatic stage (AJCC cancer staging manual).